Pbrm1 mutation as a predictive biomarker for immunotherapy in multiple cancers

HIGHLIGHTS

• who: PBRM et al. from the European University Cyprus, Cyprus Tongji hospital, China have published the research: PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers, in the Journal: (JOURNAL)
• how: To evaluate the predictive functions of PBRM1 in ICI-treated patients the clinical data and whole exome sequencing (WES) data were collected from seven published immunotherapy studies on cBioPortal (https// www.cbioportal.org) (Snyder et_al 2014 Rizvi et_al 2015 Van Allen et_al 2015 Hugo et_al 2016 Hellmann et_al 2018 Miao et_al 2018a Miao et_al 2018b). The results found that CD8+T-cells . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.